1. Home
  2. STEP vs MMED Comparison

STEP vs MMED Comparison

Compare STEP & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo StepStone Group Inc.

STEP

StepStone Group Inc.

HOLD

Current Price

$43.20

Market Cap

3.7B

Sector

Finance

ML Signal

HOLD

MMED

MiniMed Group Inc. Common Stock

N/A

Current Price

$17.12

Market Cap

4.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STEP
MMED
Founded
2007
1983
Country
United States
United States
Employees
N/A
2800
Industry
Finance/Investors Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
4.3B
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
STEP
MMED
Price
$43.20
$17.12
Analyst Decision
Buy
Strong Buy
Analyst Count
8
10
Target Price
$71.00
$22.56
AVG Volume (30 Days)
1.6M
1.1M
Earning Date
05-21-2026
06-03-2026
Dividend Yield
2.98%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,993,603,000.00
N/A
Revenue This Year
N/A
$15.99
Revenue Next Year
$26.41
$10.00
P/E Ratio
N/A
N/A
Revenue Growth
69.69
N/A
52 Week Low
$38.85
$10.65
52 Week High
$77.80
$17.86

Technical Indicators

Market Signals
Indicator
STEP
MMED
Relative Strength Index (RSI) 47.04 68.09
Support Level $41.11 $14.70
Resistance Level $49.24 N/A
Average True Range (ATR) 2.11 0.87
MACD 0.41 0.12
Stochastic Oscillator 55.97 93.49

Price Performance

Historical Comparison
STEP
MMED

About STEP StepStone Group Inc.

StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.

About MMED MiniMed Group Inc. Common Stock

Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.

Share on Social Networks: